Stock Screener
Stock Research
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

CytoDyn Shares Outstanding 2010-2024 | CYDY

CytoDyn shares outstanding from 2010 to 2024. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  
CytoDyn Annual Shares Outstanding
(Millions of Shares)
2024 970
2023 837
2022 677
2021 588
2020 421
2019 272
2018 175
2017 138
2016 95
2015 58
2014 47
2013 30
2012 25
2011 21
2010 19
2009 14
CytoDyn Quarterly Shares Outstanding
(Millions of Shares)
2024-11-30 1,221
2024-08-31 1,198
2024-05-31 970
2024-02-29 982
2023-11-30 959
2023-08-31 924
2023-05-31 837
2023-02-28 832
2022-11-30 813
2022-08-31 788
2022-05-31 677
2022-02-28 696
2021-11-30 663
2021-08-31 633
2021-05-31 588
2021-02-28 578
2020-11-30 578
2020-08-31 556
2020-05-31 421
2020-02-29 432
2019-11-30 389
2019-08-31 365
2019-05-31 272
2019-02-28 296
2018-11-30 259
2018-08-31 219
2018-05-31 175
2018-02-28 178
2017-11-30 158
2017-08-31 152
2017-05-31 138
2017-02-28 142
2016-11-30 136
2016-08-31 124
2016-05-31 95
2016-02-29 105
2015-11-30 84
2015-08-31 72
2015-05-31 58
2015-02-28 59
2014-11-30 56
2014-08-31 56
2014-05-31 47
2014-02-28 55
2013-11-30 45
2013-08-31 31
2013-05-31 30
2013-02-28 30
2012-11-30 30
2012-08-31 29
2012-05-31 25
2012-02-29 25
2011-11-30 22
2011-08-31 22
2011-05-31 21
2011-02-28 22
2010-11-30 21
2010-08-31 20
2010-05-31 19
2010-02-28 19
2009-11-30 20
2009-08-31 18
2009-05-31 14
2009-02-28 15
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.306B $0.000B
CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection. The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has completed Phase 2 clinical trials with demonstrated antiviral activity in humans and is currently in Phase 3 development. PRO 140 blocks the HIV co-receptor CCR5 on T cells, which prevents viral entry. Clinical trial results thus far indicate that PRO 140 does not negatively affect the normal immune functions that are mediated by CCR5. Results from seven Phase 1 and Phase 2 human clinical trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV. A recent Phase 2b clinical trial demonstrated that PRO 140 can prevent viral escape in patients during several months of interruption from conventional drug therapy.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) Japan $80.367B 31.71
Zoetis (ZTS) United States $70.491B 26.59
Takeda Pharmaceutical (TAK) Japan $44.101B 9.76
Daiichi Sankyo, - (DSNKY) Japan $43.319B 26.40
Sandoz Group AG (SDZNY) Switzerland $20.649B 0.00
Merck (MKKGY) Germany $18.495B 16.56
Astellas Pharma (ALPMY) Japan $17.499B 12.40
Summit Therapeutics (SMMT) United States $17.006B 0.00
United Therapeutics (UTHR) United States $16.401B 16.13
Shionogi (SGIOY) Japan $12.349B 12.37
Neurocrine Biosciences (NBIX) United States $11.577B 35.29
Orion OYJ (ORINY) Finland $7.681B 21.59
Madrigal Pharmaceuticals (MDGL) United States $7.656B 0.00
Corcept Therapeutics (CORT) United States $6.820B 51.66
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $6.245B 0.00
Stevanato Group S.p.A (STVN) Italy $6.199B 40.14
Ionis Pharmaceuticals (IONS) United States $5.197B 0.00
Grifols, S.A (GRFS) Spain $5.177B 0.00
Ono Pharmaceutical (OPHLF) Japan $4.650B 9.52
Recursion Pharmaceuticals (RXRX) United States $4.044B 0.00
Crinetics Pharmaceuticals (CRNX) United States $3.418B 0.00
Catalyst Pharmaceuticals (CPRX) United States $2.630B 11.92
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.438B 14.57
Centessa Pharmaceuticals (CNTA) United Kingdom $2.208B 0.00
Hypermarcas (HYPMY) Brazil $2.185B 0.00
Soleno Therapeutics (SLNO) United States $2.045B 0.00
BioCryst Pharmaceuticals (BCRX) United States $1.945B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $1.755B 0.00
Evotec AG (EVO) Germany $1.581B 0.00
Dyne Therapeutics (DYN) United States $1.424B 0.00
Ardelyx (ARDX) United States $1.355B 0.00
Guardian Pharmacy Services (GRDN) United States $1.273B 0.00
Indivior (INDV) United States $1.240B 5.38
ARS Pharmaceuticals (SPRY) United States $1.145B 0.00
Ocular Therapeutix (OCUL) United States $1.140B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.121B 0.00
Xencor (XNCR) United States $1.105B 0.00
Harrow (HROW) United States $1.073B 0.00
Enliven Therapeutics (ELVN) United States $1.049B 0.00
Collegium Pharmaceutical (COLL) United States $0.959B 5.24
Avadel Pharmaceuticals (AVDL) Ireland $0.816B 0.00
Bioventus (BVS) United States $0.807B 25.51
Cronos Group (CRON) Canada $0.742B 0.00
Relay Therapeutics (RLAY) United States $0.685B 0.00
Verve Therapeutics (VERV) United States $0.663B 0.00
USANA Health Sciences (USNA) United States $0.612B 11.34
Xeris Biopharma Holdings (XERS) United States $0.592B 0.00
OmniAb (OABI) United States $0.548B 0.00
Elite Pharmaceuticals (ELTP) United States $0.531B 0.00
KalVista Pharmaceuticals (KALV) United States $0.526B 0.00
Theravance Biopharma (TBPH) Cayman Islands $0.475B 0.00
Altimmune (ALT) United States $0.472B 0.00
Savara (SVRA) United States $0.462B 0.00
ProKidney (PROK) United States $0.443B 0.00
Siga Technologies (SIGA) United States $0.437B 5.10
Organogenesis (ORGO) United States $0.425B 0.00
Zevra Therapeutics (ZVRA) United States $0.418B 0.00
Akebia Therapeutics (AKBA) United States $0.417B 0.00
Aldeyra Therapeutics (ALDX) United States $0.400B 0.00
Oruka Therapeutics (ORKA) United States $0.395B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.367B 148.79
Esperion Therapeutics (ESPR) United States $0.365B 0.00
Tourmaline Bio (TRML) United States $0.317B 0.00
Ironwood Pharmaceuticals (IRWD) United States $0.304B 0.00
Aquestive Therapeutics (AQST) United States $0.279B 0.00
Korro Bio (KRRO) United States $0.268B 0.00
Heron Therapeutics (HRTX) United States $0.262B 0.00
Avita Medical (RCEL) United States $0.261B 0.00
Nature's Sunshine Products (NATR) United States $0.257B 15.31
Innate Pharma SA (IPHYF) France $0.243B 0.00
Amylyx Pharmaceuticals (AMLX) United States $0.241B 0.00
Inhibikase Therapeutics (IKT) United States $0.226B 0.00
Profound Medical (PROF) Canada $0.224B 0.00
4D Molecular Therapeutics (FDMT) United States $0.216B 0.00
Larimar Therapeutics (LRMR) United States $0.209B 0.00
MediWound (MDWD) Israel $0.201B 0.00
Lyell Immunopharma (LYEL) United States $0.193B 0.00
Nanobiotix S.A (NBTX) France $0.186B 0.00
Acrivon Therapeutics (ACRV) United States $0.182B 0.00
Enanta Pharmaceuticals (ENTA) United States $0.179B 0.00
Nektar Therapeutics (NKTR) United States $0.177B 0.00
Aclaris Therapeutics (ACRS) United States $0.165B 0.00
VAXART, INC (VXRT) United States $0.160B 0.00
Procaps Group, S.A (PROCF) Luxembourg $0.150B 0.00
Silence Therapeutics (SLN) United Kingdom $0.150B 0.00
Champions Oncology (CSBR) United States $0.145B 0.00
Inotiv (NOTV) United States $0.143B 0.00
Lexeo Therapeutics (LXEO) United States $0.133B 0.00
Cassava Sciences (SAVA) United States $0.130B 0.00
ElectroCore (ECOR) United States $0.126B 0.00
Telomir Pharmaceuticals (TELO) United States $0.124B 0.00
Achieve Life Sciences (ACHV) Canada $0.111B 0.00
Cardiol Therapeutics (CRDL) Canada $0.107B 0.00
Journey Medical (DERM) United States $0.107B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.101B 0.00
Galectin Therapeutics (GALT) United States $0.092B 0.00
Metagenomi (MGX) United States $0.091B 0.00
Arch Biopartners (ACHFF) Canada $0.087B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.084B 0.00
Regulus Therapeutics (RGLS) United States $0.083B 0.00
Nutriband (NTRB) United States $0.082B 0.00
Protara Therapeutics (TARA) United States $0.081B 0.00
Pyxis Oncology (PYXS) United States $0.081B 0.00
FibroGen (FGEN) United States $0.078B 0.00
ESSA Pharma (EPIX) Canada $0.078B 0.00
Assertio Holdings (ASRT) United States $0.077B 20.25
Karyopharm Therapeutics (KPTI) United States $0.077B 0.00
Avalo Therapeutics (AVTX) United States $0.074B 0.00
PMV Pharmaceuticals (PMVP) United States $0.073B 0.00
Mural Oncology (MURA) Ireland $0.072B 0.00
Fractyl Health (GUTS) United States $0.070B 0.00
Vivani Medical (VANI) United States $0.070B 0.00
Century Therapeutics (IPSC) United States $0.064B 0.00
Unicycive Therapeutics (UNCY) United States $0.063B 0.00
Dominari Holdings (DOMH) United States $0.063B 0.00
Gain Therapeutics (GANX) United States $0.062B 0.00
AleAnna (ANNA) United States $0.061B 0.00
OptiNose (OPTN) United States $0.060B 0.00
Context Therapeutics (CNTX) United States $0.059B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.055B 0.00
Iterum Therapeutics (ITRM) Ireland $0.052B 0.00
Rafael Holdings (RFL) United States $0.051B 0.00
Prelude Therapeutics (PRLD) United States $0.050B 0.00
AlloVir (ALVR) United States $0.050B 0.00
SCYNEXIS (SCYX) United States $0.042B 0.00
VYNE Therapeutics (VYNE) United States $0.040B 0.00
Tempest Therapeutics (TPST) United States $0.040B 0.00
NRx Pharmaceuticals (NRXP) United States $0.038B 0.00
CASI Pharmaceuticals (CASI) China $0.038B 0.00
Surrozen (SRZN) United States $0.038B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.034B 0.00
PolyPid (PYPD) Israel $0.031B 0.00
BioVie (BIVI) United States $0.030B 0.00
Incannex Healthcare (IXHL) Australia $0.029B 0.00
Jupiter Neurosciences (JUNS) United States $0.028B 0.00
Natural Alternatives (NAII) United States $0.026B 0.00
DURECT (DRRX) United States $0.025B 0.00
Scienture Holdings (SCNX) United States $0.024B 0.00
Enlivex Therapeutics (ENLV) Israel $0.022B 0.00
Mannatech (MTEX) United States $0.022B 0.00
GlycoMimetics (GLYC) United States $0.019B 0.00
Vivos Therapeutics (VVOS) United States $0.019B 0.00
Carisma Therapeutics (CARM) United States $0.019B 0.00
Lipocine (LPCN) United States $0.019B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.018B 0.00
MEI Pharma (MEIP) United States $0.018B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.017B 0.00
Traws Pharma (TRAW) United States $0.017B 0.00
Biomerica (BMRA) United States $0.016B 0.00
Citius Pharmaceuticals (CTXR) United States $0.016B 0.00
Cosmos Health (COSM) United States $0.015B 0.00
ProPhase Labs (PRPH) United States $0.014B 0.00
Lyra Therapeutics (LYRA) United States $0.013B 0.00
BioLineRx (BLRX) Israel $0.013B 0.00
Minerva Neurosciences (NERV) United States $0.013B 0.00
Nuvilex (PMCB) United States $0.013B 0.00
Phio Pharmaceuticals (PHIO) United States $0.012B 0.00
Mangoceuticals (MGRX) United States $0.012B 0.00
TherapeuticsMD (TXMD) United States $0.012B 0.00
Indaptus Therapeutics (INDP) United States $0.011B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.011B 0.00
Talphera (TLPH) United States $0.010B 0.00
Jaguar Animal Health (JAGX) United States $0.010B 0.00
Klotho Neurosciences (KLTO) United States $0.010B 0.00
Relmada Therapeutics (RLMD) United States $0.009B 0.00
Ainos (AIMD) United States $0.009B 0.00
Addex Therapeutics (ADXN) Switzerland $0.008B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.008B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.007B 0.00
Plus Therapeutics (PSTV) United States $0.007B 0.00
TransCode Therapeutics (RNAZ) United States $0.007B 0.00
Redhill Biopharma (RDHL) Israel $0.006B 0.00
CERo Therapeutics Holdings (CERO) United States $0.006B 0.00
Xenetic Biosciences (XBIO) United States $0.006B 0.00
Aptorum Group (APM) United Kingdom $0.006B 0.00
Clearmind Medicine (CMND) Canada $0.005B 0.00
SciSparc (SPRC) Israel $0.005B 0.00
Conduit Pharmaceuticals (CDT) United States $0.004B 0.00
InMed Pharmaceuticals (INM) Canada $0.004B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.004B 0.00
XORTX Therapeutics (XRTX) Canada $0.004B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.003B 0.00
Avenue Therapeutics (ATXI) United States $0.003B 0.08
Qualigen Therapeutics (QLGN) United States $0.003B 0.00
Alaunos Therapeutics (TCRT) United States $0.003B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.002B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.002B 0.00
SHINECO (SISI) China $0.002B 0.00
Heatwurx (PCSA) United States $0.002B 0.00
Aditxt (ADTX) United States $0.002B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.002B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.002B 0.00
China SXT Pharmaceuticals (SXTC) China $0.002B 0.00
Petros Pharmaceuticals (PTPI) United States $0.002B 0.00
TNF Pharmaceuticals (TNFA) United States $0.001B 0.00
PainReform (PRFX) Israel $0.001B 0.00
Universe Pharmaceuticals INC (UPC) China $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00